Search - tctmd.com

Displaying 141 - 160 of 275

Sort: Relevancy | Date

News Daily News

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

L.A. McKeown

December 11, 2017

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Todd Neale

November 01, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

Caitlin E. Cox

August 31, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Industry News

STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy of Xposition S in Left Main Artery Lesions

July 28, 2017

News Daily News

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

Shelley Wood

July 21, 2017

News Daily News

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Yael L. Maxwell

June 29, 2017

News Features EuroPCR 2017

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

Yael L. Maxwell

June 01, 2017

News Conference News EuroPCR 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

Caitlin E. Cox

May 22, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Industry News

REVA to Expand FANTOM II Trial to More Complex Cases

March 24, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Daily News

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

L.A. McKeown

March 02, 2017

News Conference News CRT 2017

Same-Day Discharge After Transradial PCI Safe, Feasible, With Significant Cost Savings

Michael O'Riordan

February 23, 2017

News Daily News

Rate of Incomplete Revascularization During PCI Is Highly Variable Across Operators

Todd Neale

February 15, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

Advertisement

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

TCTMD’s Top 10 Most Popular Stories for August 2017

ESC Updates Guidelines for Treating STEMI Patients

STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy of Xposition S in Left Main Artery Lesions

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

REVA to Expand FANTOM II Trial to More Complex Cases

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

Same-Day Discharge After Transradial PCI Safe, Feasible, With Significant Cost Savings

Rate of Incomplete Revascularization During PCI Is Highly Variable Across Operators

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content